Novo Nordisk slashes Wegovy price to US $199 for new users

USA – Novo Nordisk has introduced a limited-time offer for new U.S. self-paying patients to access the first month of its FDA-approved weight-loss drug, Wegovy, for just US $199.

This one-time promotion runs through June 30 and is part of the company’s effort to help patients move away from unapproved or compounded versions of semaglutide, the active ingredient in Wegovy.

With the full list price of Wegovy exceeding US $1,000 per month, Novo Nordisk recently began selling the medication directly to consumers for US $499 a month in cash.

The US $199 introductory rate is aimed at patients who are uninsured or whose insurance doesn’t cover the drug, offering them a more affordable starting point.

The timing of this offer aligns with a federal deadline of May 22, after which compounded versions of the drug must be pulled from the market.

Novo Nordisk’s Executive Vice President for U.S. Operations, Dave Moore, emphasized that the offer is meant to support patients transitioning from these compounded alternatives to authentic Wegovy, ensuring safety and consistency in treatment.

In a related move, LifeMD, a leading telehealth provider, announced its own limited-time introductory offer for self-pay patients prescribed Wegovy.

Through its partnership with Novo Nordisk, LifeMD is providing a US $299 bundle that includes a US $199 supply of Wegovy and US $100 worth of virtual care, onboarding, and ongoing weight management support.

The bundle is available through June 30, 2025, and will cost US $599 monthly thereafter without requiring a long-term commitment.

LifeMD’s platform delivers a complete care experience–from virtual doctor visits to prescription delivery and continuous coaching, designed to simplify access to GLP-1 therapy.

CEO Justin Schreiber highlighted the importance of offering a seamless and affordable path to weight management, especially as more patients seek legitimate alternatives to compounded treatments.